TransMedics Group, Inc. $TMDX Stock Position Raised by Legato Capital Management LLC

Legato Capital Management LLC increased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 58.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 10,565 shares of the company’s stock after purchasing an additional 3,905 shares during the period. Legato Capital Management LLC’s holdings in TransMedics Group were worth $1,185,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC purchased a new stake in TransMedics Group in the 3rd quarter worth about $28,000. Optiver Holding B.V. lifted its stake in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in TransMedics Group during the 2nd quarter worth about $48,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in TransMedics Group during the 3rd quarter valued at about $40,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

Shares of TMDX opened at $148.00 on Wednesday. The firm has a market cap of $5.08 billion, a price-to-earnings ratio of 30.20 and a beta of 1.98. The company’s fifty day moving average is $134.55 and its 200-day moving average is $126.63. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06. TransMedics Group, Inc. has a 12 month low of $62.07 and a 12 month high of $156.00.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TMDX shares. Canaccord Genuity Group increased their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Piper Sandler increased their target price on shares of TransMedics Group from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Oppenheimer lifted their target price on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $150.67.

Insider Buying and Selling

In other TransMedics Group news, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 7.00% of the stock is owned by insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.